Clinical application of the PFA-100®

被引:152
作者
Favaloro, EJ [1 ]
机构
[1] Westmead Hosp, ICPMR, Dept Hematol, Diagnost Haemostasis Lab,Western Sydney Area Hlth, Westmead, NSW 2145, Australia
关键词
D O I
10.1097/00062752-200209000-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The PFA-100((R)) (platelet function analyzer) is a relatively new tool for the investigation of primary hemostasis. Recent studies have shown its utility as a screening tool for investigating possible von Willebrand disorder (VWD) and various platelet disorders. More recently, the PFA-100((R)) has been shown to be valuable in monitoring desmopressin acetate (DDAVP) therapy in both VWD and platelet disorders. The PFA-100((R)) has also been evaluated in many other studies for its utility in assessing drug effects, for potential monitoring of antiplatelet medication (including aspirin), or for evaluation of overall primary hemostasis in various clinical disorders or during surgical procedures. This article reviews current findings and highlights the benefits and limitations of the clinical utility of the PFA-100((R)). Ultimately, the greatest strengths of the PFA-100((R)) are its simplicity of use and excellent sensitivity to particular hemostatic disturbances such as VWD, platelet disorders, and platelet-affecting medication. However, because it is thus a global test system, this also creates a significant limitation because the PFA-100((R)) is not specific for, nor predictive of, any particular disorder. However, used appropriately, the PFA-100((R)) can be considered a worthwhile addition to any hemostasis laboratory involved in the diagnosis or therapeutic monitoring of bleeding disorders and potentially of antiplatelet medication. This review should be valuable to both hemostasis scientists and clinical specialists. Curr Opin Hematol 2002, 9:407-415 (C) 2002 Lippincott Williams Wilkins, Inc.
引用
收藏
页码:407 / 415
页数:9
相关论文
共 98 条
[1]   Effect of the PlA2 alloantigen on the function of β3-integrins in platelets [J].
Bennett, JS ;
Catella-Lawson, F ;
Rut, AR ;
Vilaire, G ;
Qi, WW ;
Kapoor, SC ;
Murphy, S ;
FitzGerald, GA .
BLOOD, 2001, 97 (10) :3093-3099
[2]  
Böck M, 1999, BRIT J HAEMATOL, V106, P898
[3]   Analysis of platelet donors function before and after thrombapheresis using the platelet function analyzer PFA-100 [J].
Boehlen, F ;
Michel, M ;
Reber, G ;
de Moerloose, P .
THROMBOSIS RESEARCH, 2001, 102 (01) :49-52
[4]   RETRACTED: Changes of haemostasis. in patients undergoing major abdominal surgery - is there a difference between elderly and younger patients? (Retracted Article) [J].
Boldt, J ;
Hüttner, I ;
Suttner, S ;
Kumle, B ;
Piper, SN ;
Berchthold, G .
BRITISH JOURNAL OF ANAESTHESIA, 2001, 87 (03) :435-440
[5]  
Borzini P, 1999, HAEMATOLOGICA, V84, P1104
[6]   Platelet hemostasis capacity in smokers in vitro function analyses with 3.2% citrated whole blood [J].
Brockmann, MA ;
Beythien, C ;
Magens, MM ;
Wilckens, V ;
Kuehl, P ;
Gutensohn, K .
THROMBOSIS RESEARCH, 2001, 104 (05) :333-342
[7]  
Carcao MD, 1998, BRIT J HAEMATOL, V101, P70
[8]   Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion [J].
Cattaneo, M ;
Lecchi, A ;
Agati, B ;
Lombardi, R ;
Zighetti, ML .
THROMBOSIS RESEARCH, 1999, 96 (03) :213-217
[9]  
Cattaneo M, 1999, THROMB HAEMOSTASIS, V82, P35
[10]  
Dalby M C D, 2002, Am Heart J, V143, pE1, DOI 10.1067/mhj.2002.119998